LICENSE CATEGORIES
AVAILABLE LICENSES
LICENSE INFORMATION

Polyclonal Antibodies Against Human CD20

Tech ID #: 345.4 CONNECT WITH A MANAGER FOR LICENSING

Description of Technology

University of Calgary researcher, Dr. Julie Deans, has produced three affinity-purified, polyclonal antibodies against human CD20. CD20 is a cell-surface protein expressed in most immune cells arising from the B-cell lineage and plays a role in cellular activation and proliferation. Importantly, CD20 is a recognized biomarker for a number of human disorders, including several autoimmune diseases and B-cell malignancies. As such, quality antibodies against CD20 are valuable for both pre-clinical and clinical research applications. These particular antibodies have little cross-reactivity and have been used successfully for immunoblotting, immunofluorescence and immunoprecipitation.

Figure 1. Western blots of human Ramos B cell lysates with rabbit anti-CD20 targeting the C-terminal residues 280-297 (first described in Petrie et al. (2002)).

 

Figure 2. Western blots of human Ramos B-cells lysates probed with rabbit anti-CD20N (targeting the N-terminal residues 25-41) and rabbit anti-CD20C (targeting the C-terminal residues 231-245), pre-incubated with immunizing peptide (lanes 2 and 5), irrelevant peptide (lanes 3 and 6) or no peptide (lanes 1 and 4) (Polyak et al. (1998)).

Areas of Application
  • Inflammation and immunology
  • Oncology